Compass Therapeutics announces common stock offering, no amount given

Compass Therapeutics (CMPX) announced the launch of an underwritten public offering of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Compass. Compass intends to use the net proceeds from the offering to conduct initial preparations for commercial readiness, to fund research and clinical development of its product candidates, and for general corporate purposes. Jefferies, Piper Sandler and Guggenheim Securities are acting as joint active bookrunning managers for the offering.